Hematology · Myelodysplastic SyndromesTrial Updateclinicalmid-term

Pacritinib trial for Myelodysplastic Syndromes in adults and children initiated by NCI

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/7/2026, 6:31:14 AM

Assessment confidence: 74% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of the pacritinib trial represents a significant opportunity in the treatment landscape for Myelodysplastic Syndromes, a condition with limited effective therapies. Positive trial outcomes could enhance pacritinib's market positioning and influence future development strategies for hematology-focused companies. Regulatory context from FDA (FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease) supports the near-term read. Assessment grounded in 10 ranked evidence items (7 high-relevance).

Strategic Assessment

Portfolio teams should monitor the trial's progress as positive outcomes could enhance pacritinib's market positioning and inform future development strategies. The strongest clinical anchor is Pacritinib, Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplas (ClinicalTrials.gov), sub-indication match (ild); entity match (pacritinib). In ild, 5 regulatory and 0 competitive items passed relevance filtering for Pacritinib.

Competitive Pressure

The most relevant competitive pressure comes from This trial may position pacritinib as a potential treatment option in a space with limited effective therapies, impacting competitors focused on MDS..

Regulatory Outlook

Regulatory risk is concentrated around FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease (FDA). Sub-indication match (ild); Regulatory pathway relevance (approval). Relevant agencies in corpus: FDA, PMDA, MHRA. The trial's outcomes may influence future regulatory approvals and labeling for pacritinib, particularly if it demonstrates efficacy in a patient population with limited treatment options.

Key Risks

Elevated medium regulatory exposure for Pacritinib could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If successful, pacritinib could capture market share in a niche area with unmet needs, potentially leading to increased revenue for the sponsoring entities and impacting competitors.
Upside for Pacritinib may improve if Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should monitor the trial's progress as positive outcomes could enhance pacritinib's market positioning and inform future development strategies.

What Would Change This Assessment

This becomes more urgent if Key milestones include patient enrollment rates, interim results, and overall trial outcomes over the planned 8-year duration.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease
FDAhigh relevance
Sub-indication match (ild); Regulatory pathway relevance (approval)
FDA document
View source
FDA AP — CHILDREN'S ADVIL-FLAVORED (SUPPL)
FDAhigh relevance
Sub-indication match (ild); Regulatory pathway relevance (nda)
FDA document
View source
[ANZEN]PMDA Alert for Proper Use of Drugs: Serious hypocarnitinemia and hypoglycaemia in children treated with antibacterials with a pivoxil group (follow-up report) posted
PMDAhigh relevance
Sub-indication match (ild)
FDA document
View source
Lower dose needle-free allergy treatment approved for younger children
MHRAhigh relevance
Sub-indication match (ild)
FDA document
View source
FDA Clears First Over-the-Counter Continuous Glucose Monitor for Children
FDAhigh relevance
Sub-indication match (ild)
FDA document
View source
FDA Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Pacritinib, Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplas
ClinicalTrials.govhigh relevance
Sub-indication match (ild); Entity match (pacritinib)
FDA document
View source
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
ClinicalTrials.govhigh relevance
Sub-indication match (ild); Entity match (national cancer institute)
FDA document
View source
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
ClinicalTrials.govmedium relevance
Entity match (national cancer institute)
FDA document
View source
Study of Voicing My CHOiCES as Tool for Advanced Care Planning in Young Adults With Cancer
ClinicalTrials.govmedium relevance
Entity match (national cancer institute)
FDA document
View source
Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms
ClinicalTrials.govmedium relevance
Entity match (pacritinib)
FDA document
View source

No evidence in this category.

Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Burden of HPV-associated cancers in Peruvian men: Evidence from national health data.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Sentinel Lymph Node Mapping with Indocyanine Green in Endometrial Cancer: Does the Minimally Invasive Platform Matter?
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Pacritinib
National Cancer Institute
competitors in hematology

Commercial impact

medium

If successful, pacritinib could capture market share in a niche area with unmet needs, potentially leading to increased revenue for the sponsoring entities and impacting competitors.

Regulatory impact